Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer
Stopped early · Phase 1
Conditions studied: Metastatic Castration Resistant Prostate Cancer
In brief
This is a phase 1, first-in-human study to evaluate Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207 alone or with low dose interleukin-2 or Pembrolizumab, in patients with therapy refractory metastatic castration resistant prostate cancer.
Key facts
- Study ID
- NCT05369000
- Run by
- Lava Therapeutics
- People needed
- 96
- Starts
- 2022-01-17
- Expected to finish
- 2025-06-18
- Last updated by the study team
- 2025-08-01
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- UCSF Medical Center at Parnassus — San Francisco, California, United States
- M Health Fairview University of Minnesota Medical Center — Minneapolis, Minnesota, United States
- Washington University School of Medicine in St. Louis — St Louis, Missouri, United States
- NYU Langone Health — New York, New York, United States
- Duke University Medical Center - Duke Cancer Center — Durham, North Carolina, United States
- Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah, United States
- Radboud Universiteit - Radboud Universitair Medisch Centrum (Radboudumc) — Nijmegen, Gelderland, Netherlands
- Erasmus MC (Erasmus Universitair Medisch Centrum Rotterdam) — Rotterdam, South Holland, Netherlands
- Amsterdam UMC - VU Medisch Centrum (VUmc) — Amsterdam, Netherlands
- ICO Hospitalet (Hospital Duran i Reynals) — Barcelona, Spain
- Hospital Universitartio 12 De Octubre — Madrid, Spain
- Centro Integral Oncologico Clara Campal (HM CIOCC) — Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.